Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders

Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].